Product Description
Aleglitazar is a dual peroxisome proliferator-activated receptor (PPAR) agonist, with hypoglycemic activity. Aleglitazar binds to both PPARalpha and PPARgamma and decreases plasma levels of glucose, LDL-C, triglycerides (TG) and increases HDL levels. This agent may be used for the treatment of diabetes and cardiovascular disease. (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Aleglitazar)
Mechanisms of Action: PPAR Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Hoffmann-La Roche
Company Location:
Company CEO: Severin Schwan
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Type 2 Diabetes|Kidney Failure, Chronic|Acute Coronary Syndrome
Phase 2: Type 2 Diabetes|Kidney Diseases|Insulin Resistance|Heart Failure|Coronary Artery Disease|Myocardial Ischemia
Phase 1: Healthy Volunteers|Type 2 Diabetes
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT01615354 |
BP25559 | P1 |
Completed |
Healthy Volunteers |
2013-01-01 |
2019-03-19 |
||
NCT01701739 |
BP25562 | P1 |
Completed |
Healthy Volunteers |
2013-01-01 |
2019-03-19 |
Treatments |
|
NCT01711775 |
BP25230 | P1 |
Completed |
Healthy Volunteers |
2012-12-01 |
2019-03-19 |
Treatments |
|
NCT01679639 |
BP25561 | P1 |
Completed |
Healthy Volunteers |
2012-12-01 |
2019-03-19 |
Treatments |
|
NCT01398267 |
BP25328 | P1 |
Completed |
Type 2 Diabetes |
2012-10-01 |
2019-03-19 |
Treatments |
|
NCT01197911 |
BP25240 | P1 |
Completed |
Healthy Volunteers |
2011-08-01 |
2019-03-19 |
Treatments |
|
NCT01188304 |
BP25329 | P1 |
Completed |
Healthy Volunteers |
2010-10-01 |
2019-03-19 |
Treatments |
|
2012-002649-39 |
2012-002649-39 | P2 |
Terminated |
Type 2 Diabetes |
2013-09-03 |
2022-03-13 |
Treatments |
|
NCT01680978 |
BC25445 | P2 |
Completed |
Coronary Artery Disease|Myocardial Ischemia|Type 2 Diabetes |
2013-09-01 |
2019-03-19 |
Treatments |
|
NCT01729403 |
WC28038 | P2 |
Completed |
Insulin Resistance|Type 2 Diabetes |
2013-09-01 |
2019-03-19 |
Treatments |
|
2012-001639-29 |
2012-001639-29 | P2 |
Terminated |
Type 2 Diabetes |
2013-07-10 |
2022-03-13 |
Treatments |
|
2009-012270-12 |
2009-012270-12 | P2 |
Completed |
Type 2 Diabetes |
2012-07-05 |
2022-03-13 |
Treatments |
|
NCT01043029 |
BC22419 | P2 |
Completed |
Type 2 Diabetes|Kidney Diseases |
2012-07-01 |
2019-03-19 |
Treatments |
|
NCT00461006 |
BC20653 | P2 |
Completed |
Type 2 Diabetes |
2008-09-01 |
2019-03-21 |
Treatments |
|
NCT00388518 |
BM17864 | P2 |
Completed |
Type 2 Diabetes |
2008-03-01 |
2019-03-21 |
Treatments |
|
NCT01893242 |
Alerenal Study | P3 |
Withdrawn |
Kidney Failure, Chronic|Type 2 Diabetes |
2019-01-01 |
2019-03-19 |
Treatments |
|
NCT01715818 |
BC28027 | P3 |
Completed |
Type 2 Diabetes |
2013-11-01 |
2019-03-19 |
Treatments |
|
NCT01042769 |
BC22140 | P3 |
Completed |
Type 2 Diabetes|Acute Coronary Syndrome |
2013-11-01 |
2019-03-19 |
||
NCT01871428 |
YC28037 | P3 |
Completed |
Type 2 Diabetes |
2013-11-01 |
2019-03-19 |
Treatments |
|
NCT01691846 |
BC28035 | P3 |
Completed |
Type 2 Diabetes |
2013-09-01 |
2019-03-19 |
Treatments |
|
NCT01691989 |
WC28325 | P3 |
Completed |
Type 2 Diabetes |
2013-09-01 |
2019-03-19 |
Treatments |
|
NCT01691755 |
BC28034 | P3 |
Completed |
Type 2 Diabetes |
2013-09-01 |
2019-03-19 |
Treatments |
|
NCT01871415 |
YC28036 | P3 |
Completed |
Type 2 Diabetes |
2013-08-01 |
2019-03-19 |
Treatments |
|
2009-012269-71 |
Alecardio | P3 |
Terminated |
Acute Coronary Syndrome|Type 2 Diabetes |
2013-07-10 |
2022-03-13 |
Treatments |
|
2012-000671-16 |
AlePrevent | P3 |
Terminated |
Type 2 Diabetes |
2013-07-10 |
2022-03-13 |
Treatments |